RVMD Revolution Medicines Corp: Forward Price-to-Revenue Multiple

Brandmark of RevMed (RVMD)

Revolution Medicines (RVMD) possesses colossal market influence due to the creation of unique RAS protein inhibitors. The forward P/S history demonstrates price volatility, with the current metric standing at 188.70. High clinical trial costs are creating a temporary liquidity deficit. However, success in lung and pancreatic cancer therapies will become a powerful driver for business valuation growth.

RVMD Revolution Medicines, Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Revolution Medicines, Inc. (RVMD)

- current price and projected stock value:
General company analysis:Revolution Medicines Corp RVMD
Manufactured products of revmed.com

For oncology biopharmaceutical company Revolution Medicines (RVMD), whose stability depends on the control of raw material supply chains, the forward P/S ratio serves as an indicator of fundamental resilience relative to future revenues. By analyzing the forward P/S chart on the GURU.Markets platform, an investor compares market capitalization with expected revenue, which allows for the timely identification of asset overheating and the balancing of portfolio risks.

Analysis of competing companies

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|ascentage.com - Forward P/S Multiple|Forward Price to Sales CGON (cgoncology.com)|URGN: Forward P/S Multiple|Bicara Therapeutics Inc (BCAX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio personalis.com|Forward Price-to-Revenue Multiple Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Market Cap to Expected Sales Ratio Y-mAbs Therapeutics, Inc.|Forward P/S Multiple AURA (Aura Biosciences Inc)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple